Sun Pharma Share Price in Focus; Approves ₹3,000 Crore Greenfield Manufacturing Facility

Sun Pharmaceutical Industries Limited has announced a significant investment through its wholly-owned subsidiary, Sun Pharma Laboratories Limited.  

The company plans to invest ₹3,000 crore in establishing a greenfield formulations manufacturing facility in Madhya Pradesh. 

Investment in Madhya Pradesh Manufacturing Facility 

The Board of Directors of Sun Pharma Laboratories Limited has approved a substantial investment of ₹3,000 crore. This investment will be directed towards setting up a new greenfield formulations manufacturing facility in Madhya Pradesh.  

The decision aligns with the company's strategy to expand its manufacturing capabilities and enhance its production capacity. 

The new facility is expected to bolster Sun Pharma's production capabilities, allowing the company to meet increasing demand and explore new market opportunities. This strategic move is anticipated to contribute significantly to the company's growth trajectory in the coming years. 

Strategic Expansion Plans 

Sun Pharma's decision to invest in a new facility underscores its commitment to expanding its manufacturing footprint in India. The greenfield project in Madhya Pradesh is part of a broader strategy to enhance the company's production capabilities and ensure a robust supply chain. 

The investment is expected to create numerous job opportunities in the region, contributing to the local economy. Moreover, the facility will be equipped with state-of-the-art technology to ensure high-quality production standards. 

Read More: Sun Pharma Launches Its Global Psoriasis Drug ILUMYA® in India! 

Sun Pharmaceutical Industries Share Price Performance  

As of December 3, 2025, at 9:26 AM, Sun Pharmaceutical Industries share price on NSE was trading at ₹1,804.00 up by 0.25% from the previous closing price.  

Conclusion 

Sun Pharmaceutical Industries' approval of a ₹3,000 crore investment for a greenfield project in Madhya Pradesh marks a significant step in its expansion strategy. The new facility is poised to enhance the company's manufacturing capabilities and support its growth ambitions in the pharmaceutical sector. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.